Rapport d’analyse de la taille, de la part et des tendances du marché mondial de la thérapie cellulaire – Aperçu et prévisions de l’industrie jusqu’en 2031

Analyse du marché de la thérapie cellulaire

Le marché de la thérapie cellulaire a connu un essor considérable ces dernières années, stimulé par les progrès de la médecine régénérative et la prévalence croissante des maladies chroniques. La thérapie cellulaire implique l'administration de cellules vivantes pour traiter ou prévenir des maladies, offrant des solutions innovantes pour des pathologies telles que le cancer, le diabète et les maladies auto-immunes. Les développements récents dans le domaine comprennent des percées dans la thérapie cellulaire CAR-T pour les hémopathies malignes et des innovations dans les thérapies par cellules souches pour diverses applications médicales. Le marché se caractérise par un nombre croissant d' essais cliniques et des investissements croissants dans la recherche et le développement, en particulier dans les approches de médecine personnalisée. En outre, le soutien réglementaire et la demande croissante d'options de traitement avancées propulsent davantage la croissance du marché. Alors que les systèmes de santé reconnaissent de plus en plus le potentiel des thérapies cellulaires , le marché est prêt à poursuivre son expansion, offrant des opportunités à la fois aux entreprises établies et aux acteurs émergents du paysage biopharmaceutique.

Taille du marché de la thérapie cellulaire

Français La taille du marché mondial de la thérapie cellulaire a été évaluée à 17,75 milliards USD en 2023 et devrait atteindre 72,35 milliards USD d'ici 2031, avec un TCAC de 19,20 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Tendances du marché de la thérapie cellulaire

« Développement de thérapies efficaces »

The cell therapy market is experiencing transformative changes driven by innovation and a focus on personalized medicine. Recent advancements in technology, such as gene editing and cell engineering, are enabling the development of more effective therapies tailored to individual patient needs. One significant trend is the increasing adoption of CAR-T cell therapies, which have shown remarkable success in treating specific types of blood cancers. This trend highlights the shift towards targeted therapies that enhance treatment efficacy while minimizing side effects. Overall, the cell therapy market is evolving rapidly, with ongoing research and collaborations among biopharmaceutical companies and academic institutions paving the way for novel therapies that promise to revolutionize patient care and improve health outcomes.

Report Scope and Cell Therapy Market Segmentation

Cell Therapy Market Definition

Cell therapy is a medical treatment that involves the administration of living cells to replace or repair damaged tissues and cells in the body. This innovative approach can utilize various types of cells, including stem cells, immune cells, and differentiated cells, to target specific diseases or conditions. Cell therapy aims to restore normal function by regenerating tissues, modulating immune responses, or directly killing cancer cells. It is a key component of regenerative medicine and has shown promise in treating a range of conditions, including cancers, genetic disorders, and degenerative diseases. Advances in cell therapy research and technology continue to enhance its effectiveness and applicability in clinical settings.

Cell Therapy Market Dynamics

Drivers

• Growing Incidence of Chronic Diseases

The growing incidence of chronic diseases, including cancer, diabetes, and neurodegenerative disorders, significantly fuels the demand for innovative therapeutic solutions such as cell therapy. As the global population ages and lifestyle-related health issues rise, the need for effective treatments has never been more critical. Cell therapies, which harness the body’s own cells or modified cells to combat disease, offer promising alternatives to traditional therapies. They aim to manage symptoms and address the root causes of diseases, particularly in conditions where conventional treatments may fall short. The advancements in cell processing and technology are further enhancing the efficacy and safety of these therapies, making them attractive options for patients and healthcare providers alike. Consequently, this increasing prevalence of chronic conditions is a significant market driver, prompting ongoing research, investment, and development in the cell therapy sector.

• Advancements in Research and Technology

 Continuous advancements in cell processing, engineering, and manufacturing techniques are significantly enhancing the effectiveness and safety of cell therapies, thereby attracting increased investments and interest in the field. Innovations in these areas enable researchers and developers to create more efficient methods for cell isolation, expansion, and modification, leading to higher-quality therapeutic products. Improved engineering techniques, such as gene editing and cell reprogramming, allow for the customization of therapies tailored to individual patient needs, further increasing their efficacy. In addition, enhanced manufacturing processes ensure consistency and scalability, which are crucial for meeting growing market demands. As a result, pharmaceutical companies and biotech firms are increasingly investing in research and development to explore new applications for cell therapies. This trend drives market growth positions cell therapy as a critical component in the evolving landscape of modern medicine, addressing various unmet medical needs.

Opportunities

• Expansion of Clinical Applications

The increasing acknowledgment of cell therapies for a diverse array of medical conditions is driving substantial growth in the market. Conditions such as cancers, autoimmune diseases, and degenerative disorders have traditionally posed significant treatment challenges. However, advancements in cell therapy techniques have shown promise in addressing these complex health issues, leading to improved patient outcomes. As more healthcare professionals and researchers recognize the potential of these therapies, there is an expanding focus on clinical trials and product development. This broadening scope enhances the therapeutic arsenal available to patients and opens significant opportunities for market expansion. Companies are investing in innovative research, positioning themselves to capitalize on this growing demand for effective cell-based treatments in various therapeutic areas.

• Advancements in Regenerative Medicine

The integration of cell therapy with regenerative medicine practices is revolutionizing treatment approaches for various medical conditions, presenting significant market opportunities. This synergy enables the development of innovative therapies aimed at restoring or replacing damaged tissues and organs, which is crucial for conditions such as heart disease, spinal cord injuries, and orthopedic disorders. By leveraging the unique properties of stem cells and other cell types, researchers can create targeted treatments that promote healing and enhance overall patient outcomes. Furthermore, as advancements in biomaterials and engineering techniques progress, the potential for creating functional tissue constructs increases. This convergence of cell therapy and regenerative medicine positions the market for substantial growth, as healthcare providers seek effective solutions that address the underlying causes of injuries and diseases, rather than just managing symptoms.

Restraints/Challenges

• High Manufacturing Costs

The production of cell therapies is characterized by complex and sophisticated processes that require advanced technology and specialized facilities. These intricacies often result in high manufacturing costs, which can create barriers to accessibility for healthcare providers and patients. The need for stringent quality control measures and compliance with regulatory standards further exacerbates these expenses. As a result, smaller companies may struggle to compete with larger firms that have more resources, limiting the overall scalability of cell therapies. This challenge restricts the availability of innovative treatments and raises concerns about equity in healthcare, as some patients may not have access to the latest therapies due to financial constraints.

•  Shortage of Skilled and Trained Professionals

The increasing demand for trained professionals in the field of cell therapy highlights a significant challenge: a shortage of skilled scientists and technicians. As the industry rapidly evolves and expands, the need for qualified personnel capable of developing, manufacturing, and administering cell therapies becomes more critical. This talent gap can hinder innovation and slow down progress in research and clinical applications. In addition, the lack of adequately trained individuals may lead to suboptimal implementation of new technologies and methodologies, potentially compromising the safety and efficacy of treatments. To fully realize the potential of cell therapy, it is essential to invest in education and training programs that cultivate a workforce equipped to meet the complexities of this advanced therapeutic area.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Cell Therapy Market Scope

The market is segmented on the basis of technology, type, cell type, cell source, application, and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• Three-Dimensional Technology

Type

• Autologous
• Allogeneic

Cell Type

• Stem Cell
• Non-Stem Cell

Cell Source

• iPSCs
• Bone Marrow
• Umbilical Cord Blood-Derived Cells
• Adipose Tissues
• Neural Stem Cell

Application

• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Wounds and Injuries
• Ocular
• Others

End-User

• Hospitals and Clinics
• Regenerative Medicine Centres
• Diagnostic and Research Centres
• Others

Cell Therapy Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, technology, type, cell type, cell source, application, and end-users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the global cell therapy market, thanks to its robust healthcare infrastructure and a high concentration of key industry players. The region's extensive network of healthcare facilities facilitates advanced treatment options and innovative research. In addition, a significant population grappling with chronic disorders further drives the demand for effective cell therapies, solidifying North America's position in this market.

Asia-Pacific region is poised for substantial growth in the global cell therapy market from 2024 to 2031. This expansion is fueled by increased government initiatives aimed at enhancing healthcare access and rising public awareness regarding health issues. Furthermore, the demand for advanced medical technologies to treat chronic conditions, combined with a large population and a growing emphasis on quality healthcare, positions the region as a key player in the cell therapy landscape.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Cell Therapy Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Cell Therapy Market Leaders Operating in the Market Are:

• Kolon TissueGene, Inc. (U.S.)
• JCR Pharmaceuticals Co. Ltd. (Japan)
• MEDIPOST (South Korea)
• Stemedica Cell Technologies Inc. (U.S.)
• NuVasive Inc. (U.S.)
• Castle Creek Biosciences, Inc.  (U.S.)
• Cellectis (France)
• BioNTech IMFS (Germany)
• Pluri Biotech Ltd. (Israel)
• PRAXIS HEALTHCARE & PHARMACEUTICALS PVT. LTD. (U.S.)
• PHARMICELL Co. Ltd (South Korea)
• ANTEROGEN CO. LTD. (South Korea)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Celyad Oncology SA (Belgium)
• Regen BioPharma, Inc. (U.S.)
• Advancells (India)

Latest Developments in Cell Therapy Market

• In October 2023, Aurion Biotech initiated a phase 1/2 clinical trial in the United States to evaluate its cell therapy aimed at treating corneal edema. This study marks a significant advancement in exploring innovative treatment options for this eye condition. The trial's progression will be closely monitored as it seeks to demonstrate the therapy's safety and efficacy in patients
• En octobre 2023, Nkarta, Inc. a reçu l'approbation de la FDA pour sa demande d'IND (Investigational New Drug) visant à étudier le NKX019, une thérapie cellulaire CAR NK allogénique ciblant le CD19. Cette thérapie vise à fournir une nouvelle option de traitement pour la néphrite lupique, une maladie auto-immune difficile. Cette approbation marque une étape cruciale dans l'avancement du NKX019 vers les essais cliniques, où son efficacité et sa sécurité seront évaluées
• En juin 2023, Vertex Pharmaceuticals Incorporated s'est associée à Lonza pour créer une coentreprise visant à améliorer la production des thérapies expérimentales à base de cellules souches de Vertex. Cette collaboration cible spécifiquement les traitements du diabète de type 1 (DT1), en se concentrant sur les programmes d'essais cliniques VX-880 et VX-264. L'initiative devrait rationaliser les processus de fabrication et soutenir l'avancement de ces thérapies prometteuses
• En mai 2023, Johnson & Johnson a conclu un accord mondial de collaboration et de licence avec Cellular Biomedicine Group pour co-développer des thérapies CAR-T avancées. Ce partenariat vise à innover et à améliorer l'efficacité des traitements CAR-T, reflétant l'engagement des deux entreprises à faire progresser les thérapies contre le cancer. Cette collaboration devrait accélérer le développement de ces thérapies de nouvelle génération dans le domaine de l'oncologie
• En mars 2023, Adaptimmune Therapeutics plc et TCR2 Therapeutics ont annoncé un partenariat stratégique visant à établir une organisation de thérapie cellulaire de premier plan axée sur le traitement des tumeurs solides. Cette alliance vise à tirer parti de l'expertise et des ressources de chaque entreprise pour faire progresser les thérapies innovantes dans ce domaine complexe de l'oncologie. Cette collaboration reflète un engagement commun à améliorer les options de traitement et les résultats pour les patients atteints de cancers à tumeurs solides        

SKU-28214